Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy
Christopher P. Cannon, MD*,
Benjamin A. Steinberg, BA,
Sabina A. Murphy, MPH,
Jessica L. Mega, MD and
Eugene Braunwald, MD
Thrombolysis In Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
View larger version (18K):
[in a new window]
|
Figure 1 Low-density lipoprotein cholesterol (LDL-C) levels of trials comparing high-dose to standard-dose statin therapy. *Values for trials are estimated means, as not all individual LDL-C measurements were available.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Individual trials and pooled analysis showing a highly significant 16% reduction in the risk of coronary death or myocardial infarction (p < 0.0001). CI = confidence interval; OR = odds ratio.
|
|
View larger version (10K):
[in a new window]
|
Figure 3 Individual trials and pooled analysis showing a highly significant 16% reduction in the risk of coronary death or any cardiovascular event (myocardial infarction, stroke, hospitalization for unstable angina, or revascularization) (p < 0.0001). CI = confidence interval; OR = odds ratio.
|
|
View larger version (25K):
[in a new window]
|
Figure 4 Individual and pooled analyses showing non-significant trend in reduction of cardiovascular death (A), no increased risk of non-cardiovascular mortality (B), and a non-significant trend toward decreased overall mortality with high-dose statins (C). CI = confidence interval; OR = odds ratio.
|
|
View larger version (17K):
[in a new window]
|
Figure 5 Individual and pooled analyses demonstrating a significant 18% reduction of stroke with intensive statin therapy. CI = confidence interval; OR = odds ratio.
|
|
|
